Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01105832|
Recruitment Status : Completed
First Posted : April 19, 2010
Last Update Posted : December 10, 2014
40 postmenopausal women, with a non-operated proximal humeral fracture, will be randomized to standard treatment (physiotherapy) or standard treatment + Forsteo (rhPTH 1-34) during 4 weeks. Follow-up will be at 7 weeks and 3 months including x-ray and DASH score (The Disabilities of the Arm, Shoulder and Hand) measuring physical function, and pain on a visual analoge scale (VAS).
Two doctors, blinded to the treatment, will judge the callus formation and healing on the x-rays and guess the treatment. The DASH score and the pain score will be compared between the treatment groups.
The investigators hypotheses are that callus formation and healing will be more pronounced and that patients have less pain and better function in the rhPTH 1-34 group.
|Condition or disease||Intervention/treatment||Phase|
|Humeral Fracture||Drug: Teriparatide||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||September 2014|
Experimental: Proximal humeral fracture - intervention
20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
Teriparatide (Forsteo) 20 micrograms daily during four weeks
No Intervention: Proximal humeral fracture
20 patients will receive standard treatment (physiotherapy)
- Callus formation and fracture healing at 7 weeks judged by a blinded assessor who will guess the treatment [ Time Frame: 7 weeks ]
- Function [ Time Frame: 7 weeks and 3 months ]The function in the upper extremity will be measured using DASH. The experimental group will be compared with the control group
- Pain [ Time Frame: 7 weeks and 3 months ]Pain at rest and during activity will be measured using a visual analogue scale (VAS). The experimental group will be compared with the control group
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01105832
|Lasarettet i Motala|
|Department of Orthopaedics|